Interpretation of updated NCCN clinical practice guidelines for lung cancer screening (version 2. 2022)

VernacularTitle:2022年第二版《NCCN肺癌筛查临床实践指南》解读
Author: Haojie SI ¹ ; Long XU ¹ ; Fang WANG ¹ ; Hang SU ¹ ; Yunlang SHE ¹ ; Chenyang DAI ¹ ; Xuefei HU ¹ ; Deping ZHAO ¹ ; Yuming ZHU ¹ ; Peng ZHANG ¹ ; Gening JIANG ¹ ; Chang CHEN ¹
Author Information

1. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, P. R. China
Publication Type:Journal Article
Keywords: Lung cancer screening; NCCN guideline; interpretation of guideline
From: Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2022;29(11):1407-1413
CountryChina
Language:Chinese
Abstract: Lung cancer is the most common cancer and the leading cause of cancer-related death in China. Early screening of lung cancer proves to be effective in improving its prognosis. The National Comprehensive Cancer Network (NCCN) has updated and released version 2, 2022 NCCN clinical practice guidelines for lung cancer screening in July, 2022. Based on high-quality clinical evidence and the latest research progress, the guidelines have developed and updated criteria for lung cancer screening which have been widely recognized by clinicians around the world. Compared with Chinese lung cancer screening guidelines, this article will interpret the updated content of the brand new 2022 NCCN screening guidelines, providing some reference for the current lung cancer screening practice in our country.